Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851297 | 0.83 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1306384 | 0.82 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL18526935 | 0.81 | ALDH1A1 (0.48) | APP | |
| SCHEMBL1306505 | 0.79 | APP (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL711868 | 0.79 | ALDH1A1 (0.46) | APP | |
| SCHEMBL4107898 | 0.79 | APP (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12477568 | 0.77 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL14882956 | 0.76 | ALDH1A1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1098721 | 0.76 | ALDH1A1 (0.45) | — | |
| SCHEMBL672198 | 0.76 | APP (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658861-B1 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | UNIV ADAM MICKIEWICZ (PL) | 2016-10-12 | — | — | EP | disclosed |
| US-9108994-B2 | (Triorganosilyl)alkynes and their derivatives and a new catalytic method for obtaining new and conventional substituted (triorganosilyl)alkynes and their derivatives | ADAM MICKIEWICZ UNIVERSITY (PL) | 2015-08-18 | — | — | US | disclosed |
| US-20140005427-A1 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | ADAM MICKIEWICZ UNIVERSITY (PL) | 2014-01-02 | — | — | US | disclosed |
| EP-2658861-A2 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | Adam Mickiewicz University (PL) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012091588-A2 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | ADAM MICKIEWICZ UNIVERSITY (PL) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005427-A1 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | TPI1, ALK, INO80C | GABRA1 3163/4885GABRG2 4204/4885GABRB3 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.